TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Innovative Treatment for Fistula-in-ano in Crohn Disease : Local Micro Reinjection of Autologous Fat and SVF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Disease of Crohn diagnosed for at least 6 months according to the recognized clinical, endoscopic and histological criteria~* Presence of fistulas died anal complex estimated by clinical examination and MRI. A fistula died anal complex is, by definition, a fistula which answers at least one of the following criteria during its evolution: (1) high, trans-sphincter, extra-sphincter or above sphincter Inter-sphincter. (2) Presence of = 2 external openings. (3) Purulent Collections associated~* Active or slightly active Crohn luminal, defined by a CDAI (Crohn's Disease Activity Index) = 220~Exclusion Criteria:~- Disease of Crohn activates mainly luminal with a CDAI = 220 requiring an immediate treatment~* Patients having never received specific treatments of the anal died disease of Crohn with fistula, including by antibiotics~* Presence of an abscess or collections of more than 2 cms unless this problem is solved during the period of preparation~* Rectal and/or anal Stenosis and/or active proctitis, if it means a limitation of the surgical procedure~* Patient having undergone an operation of the fistula other than the drainage~* Patients under corticoids or by having receiving in the previous four weeks~* Active Malignant Tumors or history of Malignant tumors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Crohn's disease treated by SVF (Type: EXPERIMENTAL): Patients with Crohn's disease and fistula-in-ano refractory to conventional medical and surgical treatment, treated by Stromal Vascular Fraction ( SVF) reinjection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Main inclusion criteria include:~* Patients with CML in blast crisis, CML in accelerated phase defined as never in blast crisis phase, or CML in chronic phase defined as never been in blast crisis phase or accelerated phase who have: \*developed progressive disease during therapy with at least 600 mg of imatinib per day, -OR- \*patients with CML on imatinib therapy, at any dose, developing progressive disease and the presence of a genetic mutation likely to result in imatinib resistance -OR- \*have developed an intolerance to imatinib~* Relapsed or refractory Ph+ ALL~* Hypereosinophilic syndrome/chronic eosinophilic leukemia.~* Systemic mastocytosis who have a clinical indication for treatment.~* Prior imatinib therapy for patients with Ph+ ALL, HES/CEL and SM is permitted but is not required~* CML patients who have been treated with an investigational tyrosine kinase inhibitor who otherwise meet the definition of imatinib-resistance or intolerance are eligible~* Written informed consent prior to any study procedures being performed~Exclusion Criteria:~* Impaired cardiac function~* Patients with severe/chronic or uncontrolled medical conditions (including but not limited to diabetes, infections, GI impairment, CNS infiltration, liver and kidney disease)~* Prior and concomitant use of certain medications (including but not limited to warfarin, chemotherapy, hematopoietic colony-stimulating growth factors, medications that can affect electrocardiogram test results, other investigational drugs )~* Women who are pregnant or breastfeeding~* Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention.~* Patients unwilling to comply with the protocol.~* Known diagnosis of human immunodeficiency virus (HIV) infection~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CML-CP With Prior Imatinib Only (Type: EXPERIMENTAL): Imatinib-resistant / intolerant PH+ CML-CP patients
- CML-AP With Prior Imatinib Onl (Type: EXPERIMENTAL): Imatinib-resistant / intolerant PH+ CML-AP patients
- CML-CP (Type: EXPERIMENTAL): Imatinib-resistant / intolerant PH+ CML-CP patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Healthy male subjects~Exclusion criteria:~1. Any relevant deviation from healthy conditions

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- BI 655075 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- BI 655075 with dabigatran (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Adults of either sex aged 50 years and older;~* SMH associated with treatment-naive or previously treated wet AMD, including retinal angiomatous proliferation (RAP) and idiopathic polypoidal choroidal vasculopathy (IPCV);~* SMH of at least 1 disc area, involving the fovea, and of sufficient density to obscure RPE detail;~* Written informed consent to participate in the study.Only one eye will be eligible for inclusion in this study.~Exclusion criteria:~* SMH that is known to have been present for greater than 2 weeks duration, as evidenced by history, pre-trial documentation, or fundus appearance;~* Presence of significant vitreous haemorrhage precluding accurate retinal assessment in the study eye;~* Diabetic maculopathy in the study eye;~* Visually significant cataract in the study eye;~* Amblyopia in the study eye;~* Presence of other ocular disease causing concurrent vision loss in the study eye;~* Advanced glaucoma in the study eye (cup-to-disc ratio greater than 0.8);~* Pregnant and or lactating women;~* Women of childbearing potential including those who are not sterilised or at least one year post menopausal;~* Participation in a clinical interventional trial in the preceding 6 months;~* Documented evidence of a visual acuity less than 25 ETDRS letters at three consecutive visits in the study eye, prior to the onset of submacular haemorrhage;~* Participants who are known to have been ineligible for NICE approved ranibizumab therapy prior to the development of the SMH;~* Current treatment for wet age-related macular degeneration with an intravitreal agent other than ranibizumab, bevacizumab or aflibercept;~* Patients who, in the opinion of the Investigator, would not be willing or able to comply with the study protocol, including posturing requirements.~* Patients who show insufficient understanding of the clinical trial or treatment options.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (A) (Type: SHAM_COMPARATOR): Ranibizumab only (active control). Participants will receive a 'sham injection' to simulate C3F8 and/or tPA administration.
- C3F8 Only Group (B) (Type: EXPERIMENTAL): C3F8 given. Ranibizumab given as standard.
- tPA and C3F8 Group (C) (Type: EXPERIMENTAL): Both C3F8 gas and tPA given. Ranibizumab given as standard.
- tPA Only Group (D) (Type: EXPERIMENTAL): tPA given. Ranibizumab given as standard.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Allopurinol and Dypiridamole in Acute Mania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The presence of manic episode was confirmed using SCID-I and the severity of episode was evaluated using the Young Mania Rating Scale (YMRS) and the Clinical Global Impression scale (CGI). Patients were required to present a score\>22 on the YMRS at screening to be included.All subjects presented good physical health determined by physical exam, medical history, blood screening and electrocardiogram~Exclusion Criteria:~* Subjects presenting rapid cycling, mixed episodes and comorbidities with axis I psychiatric disorders were not considered for inclusion. .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Lithium 900mg/day plus allopurinol 600mg/day
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Safety and Efficacy of Duloxetine in Predominant Stress Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female diagnosed with stress urinary incontinence~Exclusion Criteria:~* Currently taking a monoamine oxidase inhibitor

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Idebenone to Treat Friedreich's Ataxia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Diagnosis of FA with confirmed FRDA mutations.~Age from nine up to but not over eighteen years.~Weight between 30 to 80 kilograms.~Ambulatory (assistance devices permitted).~Willing to participate in all aspects of trial design and follow-up.~All subjects agree and commit to the use of 2 reliable methods of birth control for the duration of the study if sexually active.~Neurologically symptomatic.~No exposure to idebenone, coenzyme Q10, or other dietary supplements for a period of at least one month before enrollment in the study.~EXCLUSION CRITERIA:~History of a hypersensitivity reaction to idebenone or coenzyme Q10.~Pregnant or lactating women. All women of child-bearing potential must have negative serum pregnancy prior to the medication phase of the study. If a minor has a positive pregnancy test, we will inform her but not inform her parents unless we are asked to by the minor.~Platelet count, white blood cell count or hemoglobin below the lower limit of normal.~Alkaline phosphatase, SGOT, or SGPT greater than 1.5 times the upper limit of normal. Bilirubin greater than 1.5 g/dl.~Creatinine greater than 1.5 times the upper limit of normal based upon the pediatric reference range provided by the testing laboratory.~Clinically significant medical disease that, in the judgment of the investigators, would expose the patient to undue risk of harm or prevent the patient from completing the study.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Major Inclusion Criteria:~1. Male or female between 18 and 75 years of age, inclusive~2. Diagnosis of OSA according to ICSD-3 criteria~3. Body mass index from 18 to \<45 kg/m2~4. Consent to use a medically acceptable method of contraception~5. Willing and able to provide written informed consent~Major Exclusion Criteria:~1. Female subjects who are pregnant, nursing, or lactating~2. Any other clinically relevant medical, behavioral, or psychiatric disorder other than OSA that is associated with excessive sleepiness~3. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5 criteria~4. History or presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy, safety, PK assessments, or the ability of the subject to complete the trial per the judgment of the Investigator.~5. History of bariatric surgery within the past year or a history of any gastric bypass procedure~6. Presence or history of significant cardiovascular disease~7. Use of any over-the-counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness~8. Received an investigational drug in the past 30 days or five half-lives~9. Previous exposure to or participation in a clinical trial of JZP-110 (ADX-N05, R228060, or YKP10A)~10. History of phenylketonuria (PKU) or history of hypersensitivity to phenylalanine-derived products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 37.5 mg of JZP-110 (Type: ACTIVE_COMPARATOR): Once Daily Dosing
- 75 mg of JZP-110 (Type: ACTIVE_COMPARATOR): Once Daily Dosing
- 150 mg of JZP-110 (Type: ACTIVE_COMPARATOR): Once Daily Dosing
- 300 mg of JZP-110 (Type: ACTIVE_COMPARATOR): Once Daily Dosing
- Placebo (Type: ACTIVE_COMPARATOR): Once Daily Dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women \>/= 20 years of age in patients with confirmed acute symptomatic pulmonary embolism (PE) with or without symptomatic deep vein thrombosis (DVT)~Exclusion Criteria:~* Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of PE~* More than 48 hours pre-randomization treatment with therapeutic dosages of anti-coagulant treatment or more than a single dose of warfarin from the onset of the current episode of PE to randomization~* Calculated creatinine clearance (CLCR) \< 30 mL/min~* Subjects with hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk~* Active bleeding or high risk for bleeding contraindicating treatment with unfractioned Heparin (UFH) or warfarin~* Systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None
- Arm 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A New Approach for Controlling Hemostasis During Canal Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients aged between 20 and 60 years~* patients able and willing to sign a consent form,~* single-rooted teeth with necrotic pulp confirmed by electric vitality test~* healthy periodontium~* physiologic sulcus depth (\<3 mm)~* absence of bleeding on probing of the involved teeth.~Exclusion Criteria:~* patients with systemic diseases~* patients using anticoagulants in the last 30 days~* patients using antibiotics in the last 30 days~* patients using anti-inflammatory therapies in the last 30 days~* patients with allergy to sulfur in any form~* pregnancy.~All subjects were informed of the nature and potential risks and benefits of their participation in the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- HybenX ® (Type: EXPERIMENTAL): 1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
- Control (Type: PLACEBO_COMPARATOR): 5 cc of sterile saline water for 20 sec

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Phakic study eye~* IOP ≥ 21 mmHg and ≤ 40 mmHg at screening exam (OHT requires second screening)~Exclusion Criteria:~* Aphakic or pseudophakic eyes (AC-IOLs or PC-IOLs)~* Previous usage of topical prostaglandin analogues or prior medical therapy for glaucoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- iStent (Type: ACTIVE_COMPARATOR): Implantation of two iStent devices
- Drug (Type: ACTIVE_COMPARATOR): Travoprost drops

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Clinical Study of KHK4827

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has had stable moderate to severe plaque psoriasis for at least 6 months.~* Subject has received at least one previous phototherapy or systemic psoriasis therapy or has been a candidate to receive phototherapy or systemic psoriasis therapy in the opinion of the investigator.~* Subject has involved BSA ≥ 10% and PASI ≥ 12 at screening and at baseline.~Exclusion Criteria:~* Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced, or medication-exacerbated psoriasis.~* Evidence of skin conditions at the time of the screening visit (eg, eczema) that would interfere with evaluations of the effect of investigational product on psoriasis.~* Subject has any active Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher infection~* Subject has a significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol.~* Subject has used the following therapies within 14 days of the first dose: topical calcineurin inhibitors including tacrolimus~  , topical vitamin A, activated form D3 or activated form D3 analogue preparations, weak through strong topical steroids (excluding application on the scalp, axillae, and groin)~* Subject has used the following therapies within 28 days of the first dose: any other systemic psoriasis therapy (eg, vitamin A, calcineurin inhibitors, methotrexates, steroids), UVA therapy (with or without psoralen), very strong or strongest topical steroid, tar therapy~* Subject has used the following therapies within 3 months of the first dose: adalimumab, etanercept, infliximab, or live vaccines~* Subject has used ustekinumab within 6 months of the first dose~* Subject has previously used an anti-interleukin-17 biologic therapy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- KHK4827 70mg SC (Type: EXPERIMENTAL): None
- KHK4827 140mg SC (Type: EXPERIMENTAL): None
- KHK4827 210mg SC (Type: EXPERIMENTAL): None
- Placebo SC (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete